Leslie Meltzer - Aug 26, 2025 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief Research and Development
Signature: /s/ David Watson, attorney-in-fact for Leslie Meltzer
Stock symbol: APLS
Transactions as of: Aug 26, 2025
Transactions value $: $0
Form type: 4
Date filed: 9/2/2025, 10:13 AM
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
MELTZER LESLIE	Chief Research and Development	C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM	/s/ David Watson, attorney-in-fact for Leslie Meltzer	2025-09-02	0002084030

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Award	$0	+61.8K		$0.00	61.8K	Aug 26, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$0	+92.6K		$0.00	92.6K	Aug 26, 2025	Common Stock	92.6K	$16.20	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This restricted stock unit was granted on August 26, 2025. The restricted stock unit will vest 25% annually over four years from grant date, subject to her continued service as an officer, or upon later termination of her service.
F2	This represents a stock option award granted August 26, 2025 that vests over a four-year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.